At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BHVN Biohaven Pharmaceutical Holding Co Ltd.
Post-Market Trading 11-25 17:17:06 EST
45.23
-0.36
-0.79%
盘后45.23
+0.000.00%
16:20 EST
High47.44Low40.80Vol2.32M
Open40.80D1 Closing45.59Amplitude14.56%
Mkt Cap4.57BTradable Cap3.81BTotal Shares101.12M
T/O104.00MT/O Rate2.75%Tradable Shares84.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Biohaven Is Maintained at Outperform by RBC Capital
Dow Jones  ·  01:36
Biohaven Is Maintained at Outperform by RBC Capital
Biohaven study had positive signal for obesity, says H.C. Wainwright
TIPRANKS  ·  01:30
Biohaven study had positive signal for obesity, says H.C. Wainwright
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Benzinga  ·  00:51
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Biohaven outcome ‘fundamental net positive’ for Scholar Rock, says JPMorgan
TIPRANKS  ·  00:40
Biohaven outcome ‘fundamental net positive’ for Scholar Rock, says JPMorgan
BUZZ-U.S. STOCKS ON THE MOVE-AMC, Alnylam, Super Micro
Reuters  ·  00:15
BUZZ-U.S. STOCKS ON THE MOVE-AMC, Alnylam, Super Micro
Biohaven Ltd : RBC Cuts Target Price to $58 From $66
THOMSON REUTERS  ·  11-25 23:46
Biohaven Ltd : RBC Cuts Target Price to $58 From $66
RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating
MT Newswires Live  ·  11-25 23:39
RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating
Biohaven down 5% as spinal muscular atrophy asset misses primary endpoint
seekingalpha  ·  11-25 23:03
Biohaven down 5% as spinal muscular atrophy asset misses primary endpoint
Biohaven falls -9.0%
TIPRANKS  ·  11-25 22:50
Biohaven falls -9.0%
BUZZ-Scholar Rock hits 3-year high on rival Biohaven's drug setback
Reuters  ·  11-25 22:49
BUZZ-Scholar Rock hits 3-year high on rival Biohaven's drug setback
Biohaven Shares Dip 0.8% as Spinal Muscular Atrophy Drug Fails to Meet Study Goal
THOMSON REUTERS  ·  11-25 22:36
Biohaven Shares Dip 0.8% as Spinal Muscular Atrophy Drug Fails to Meet Study Goal
Scholar Rock Holding Shares Jump 37.5% After Rival Biohaven's Rare Genetic Disorder Drug Fails Trial Goal
THOMSON REUTERS  ·  11-25 22:31
Scholar Rock Holding Shares Jump 37.5% After Rival Biohaven's Rare Genetic Disorder Drug Fails Trial Goal
BUZZ-U.S. STOCKS ON THE MOVE-Replimune, Snowflake, Virpax Pharmaceuticals
Reuters  ·  11-25 22:20
BUZZ-U.S. STOCKS ON THE MOVE-Replimune, Snowflake, Virpax Pharmaceuticals
Sector Update: Health Care Stocks Edge Higher Premarket Monday
MT Newswires Live  ·  11-25 22:09
Sector Update: Health Care Stocks Edge Higher Premarket Monday
BUZZ-Biohaven falls as genetic disorder drug fails to meet goal in late-stage study
Reuters  ·  11-25 21:26
BUZZ-Biohaven falls as genetic disorder drug fails to meet goal in late-stage study
Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell
MT Newswires Live  ·  11-25 21:22
Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
Reuters  ·  11-25 20:43
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
BRIEF-Biohaven Provides Update On Taldefgrobep Alfa Development Program
Reuters  ·  11-25 20:43
BRIEF-Biohaven Provides Update On Taldefgrobep Alfa Development Program
Biohaven Shares Fall 12.3% Premarket as Sma Treatment Did Not Show Statistically Significant Difference on Primary Outcome in Trial
THOMSON REUTERS  ·  11-25 20:40
Biohaven Shares Fall 12.3% Premarket as Sma Treatment Did Not Show Statistically Significant Difference on Primary Outcome in Trial
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
THOMSON REUTERS  ·  11-25 20:30
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

Introduction

Company Name.
Biohaven Pharmaceutical Holding Co Ltd.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Issue price:
--